Adcendo Secures $135 Million in Series B Funding to Revolutionize Cancer Treatment with Antibody-Drug Conjugates

We are thrilled to announce that Adcendo, a pioneering biopharmaceutical company dedicated to developing innovative antibody-drug conjugates for cancer treatment, has successfully raised $135 million in its latest funding round. Founded in 2017 in Copenhagen as a spin-out from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen, Adcendo is committed to addressing the significant unmet medical needs of cancer patients through the advancement of targeted therapies. The funding will be instrumental in accelerating the company’s ambitious development program, focusing on its promising pipeline of novel drug candidates aimed at treating various forms of cancer. With the financial backing from renowned investors, Adcendo is poised to enhance its research capabilities, further explore its state-of-the-art technology, and expedite clinical trials for its groundbreaking therapies. This funding milestone underscores the profound impact that innovative companies like Adcendo can have in the fight against cancer and reflects the increasing confidence in their approach to harnessing the power of antibody-drug conjugates. As we look to the future, our team remains dedicated to transforming the treatment landscape for cancer patients, bringing hope to those who are currently underserved by existing therapies. With this significant infusion of resources, Adcendo is even better positioned to fulfill its mission of improving the lives of patients and ultimately contributing to the global effort against cancer.